A5030343988- Asthma and respiratory diseases
- IL-33, ST2, and ILC Pathways
- Allergic Rhinitis and Sensitization
- Dermatology and Skin Diseases
- Advanced NMR Techniques and Applications
- Respiratory and Cough-Related Research
- Pharmaceutical studies and practices
- Eosinophilic Esophagitis
- Intestinal Malrotation and Obstruction Disorders
- Clinical Nutrition and Gastroenterology
- Child Nutrition and Feeding Issues
- Inhalation and Respiratory Drug Delivery
- NMR spectroscopy and applications
- Library Science and Information Literacy
- Intestinal and Peritoneal Adhesions
- Congenital gastrointestinal and neural anomalies
- Advanced MRI Techniques and Applications
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Electron Spin Resonance Studies
- Advanced Chemical Physics Studies
- Gastrointestinal motility and disorders
- Diet and metabolism studies
- Molecular spectroscopy and chirality
- Infant Health and Development
- Solid-state spectroscopy and crystallography
AstraZeneca (United States)
2020-2024
Nationwide Children's Hospital
2023
AstraZeneca (Finland)
2021-2022
AstraZeneca (Brazil)
2020
Massachusetts Institute of Technology
1993-2007
University of Michigan–Ann Arbor
2005
University of Pittsburgh
2001-2003
Children's Hospital of Pittsburgh
1997-2003
Max Planck Institute of Molecular Physiology
1999
University of Pittsburgh Medical Center
1998
In some patients with moderate-to-severe asthma, particularly those noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for epithelial-cell–derived cytokine thymic stromal lymphopoietin (TSLP), in whose asthma remained uncontrolled despite treatment long-acting beta-agonists medium-to-high doses inhaled glucocorticoids.
Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. The efficacy and safety tezepelumab patients with severe, uncontrolled asthma require further assessment.
Rationale: Tezepelumab reduced exacerbations in patients with severe, uncontrolled asthma across a range of baseline blood eosinophil counts and fractional exhaled nitric oxide levels, irrespective allergy status, the phase 2b PATHWAY (Study to Evaluate Efficacy Safety MEDI9929 [AMG 157] Adult Subjects With Inadequately Controlled, Severe Asthma; NCT 02054130) 3 NAVIGATOR Adults & Adolescents Uncontrolled 03347279) trials. Objectives: To examine efficacy safety tezepelumab additional...
We discuss several aspects of homonuclear recoupling and longitudinal exchange using rotor-synchronized spin echo sequences in solid state magic-angle spinning (MAS) experiments. These include the accurate measurement weak dipole–dipole couplings between rare spins, behavior dipolar trajectories multiple environments, chemical shift correlation spectroscopy via polarization exchange. To describe accurately, we adopt an approach to simulation these experiments which includes finite pulses...
Abstract Background Patients with severe, uncontrolled asthma have a significant unmet need for new treatments that broader effects on airway inflammation, and provide greater improvements in outcomes than currently approved biologics standard-of-care therapies. Tezepelumab is human monoclonal antibody blocks the activity of epithelial cytokine thymic stromal lymphopoietin. In PATHWAY phase 2b study (NCT02054130), tezepelumab significantly reduced exacerbations by up to 71% adults asthma,...
Abstract Background Tezepelumab is a human monoclonal antibody that blocks activity of thymic stromal lymphopoietin (TSLP). In the phase IIb PATHWAY study (NCT02054130), tezepelumab significantly reduced annualized asthma exacerbation rates (AAERs) versus placebo in adults with severe, uncontrolled asthma. We evaluated effects reducing type 2 (T2) inflammatory biomarker levels population, and relationship between baseline T2 AAER. Methods Adults ( n = 550) were randomized to (70 mg or 210...
Abstract Background Many patients with severe asthma continue to experience symptoms and exacerbations despite standard-of-care treatment. A substantial proportion of these require long-term treatment oral corticosteroids (OCS), often at high doses, which are associated considerable multiorgan adverse effects, including metabolic disorders, osteoporosis adrenal insufficiency. Tezepelumab is a human monoclonal antibody that blocks the activity epithelial cytokine thymic stromal lymphopoietin....
BACKGROUND: Mucus plugs in asthmatic airways are associated with airway obstruction and the activity of inflammatory cytokines, specifically interleukin (IL)-5 IL-13, they may provide an opportunity for targeted therapy. This analysis CASCADE (Study to Evaluate Tezepelumab on Airway Inflammation Adults With Uncontrolled Asthma) placebo-controlled trial used computed tomography (CT) imaging assess mucus patients moderate-to-severe, uncontrolled asthma who received tezepelumab or placebo....
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTRotational Resonance Solid-State NMR Elucidates a Structural Model of Pancreatic AmyloidJanet M. Griffiths, Ted T. Ashburn, Michele Auger, Philip R. Costa, Robert G. Griffin, and Peter Lansbury Jr.Cite this: J. Am. Chem. Soc. 1995, 117, 12, 3539–3546Publication Date (Print):March 1, 1995Publication History Published online1 May 2002Published inissue 1 March...
BackgroundPatients with severe, uncontrolled asthma experience frequent exacerbations and hospitalization, leading to poor health-related quality of life. In the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced by up 71% improved lung function, control, life vs placebo.ObjectiveThis analysis further assessed impact on patient-reported outcomes (PROs) in PATHWAY.MethodsAdults were randomized subcutaneous (70 mg every 4 weeks, 210 or 280 2 weeks) placebo for 52 weeks. PROs using...
BackgroundTezepelumab is an anti–thymic stromal lymphopoietin mAb. In the PATHWAY phase IIb study (NCT02054130), tezepelumab significantly reduced annualized asthma exacerbation rates (AAERs) versus placebo in adults with severe, uncontrolled asthma.ObjectiveThis post hoc analysis assessed efficacy of participants perennial allergy.MethodsAdults (N = 550) were randomized to receive (70 mg or 210 every 4 weeks 280 2 weeks) placebo, for 52 weeks. The AAER over was analyzed patients grouped by...
OBJECTIVE: The aim of this study was to evaluate the role colonic manometry in clarifying pathophysiology childhood defecatory disorders and its impact on management. METHODS: We conducted a retrospective review medical records children referred undergo tertiary care Motility Center from 1996 2001. Families were followed up median 20 months after evaluation (range 3–60 months). RESULTS: A total 150 manometries performed 146 (74 male, age 79 months, range 4–225 Colonic had been requested...
The impact of past and current asthma on ventilatory function was assessed among young adults born in Britain March 3-9, 1958 who had been followed from birth to ages 7, 11, 16, 23, 33 yr. We compared 1,060 subjects with a history asthma, wheezy bronchitis, or wheezing 275 control no chest illness. Forced expiratory volume one second (FEV1) forced vital capacity (FVC) were measured at 34-35 yr age before 20 min after inhalation 400 micrograms salbutamol, adjusted for sex, height, smoking by...
To assess the benefit of antegrade enemas in children with severe constipation who were referred to a tertiary care center.From 1997 1999, 12 (9 male, aged 8.7 +/- 4.4 years) underwent cecostomy placement. All neurologically normal and had been extensively examined rule out organic causes constipation. Follow-up included questionnaire interview caregivers 13.1 8.5 months after placement.For all children, led improvement number bowel movements / week (7.1 versus 1.4, P < 0.005), soiling...
Abstract Background Respiratory virus infections are main triggers of asthma exacerbations. Tezepelumab, an anti‐TSLP mAb, reduces exacerbations in patients with asthma, but the effect blocking TSLP on host epithelial resistance and tolerance to infection is not known. Aim To examine effects (IFNβ, IFNλ, viral load) airway inflammatory response challenge. Methods Bronchoalveolar lavage fluid (BALF, n = 39) bronchial cells (BECs) were obtained from uncontrolled before after 12 weeks...
Abstract Background Allergic asthma is the most common phenotype among patients with severe asthma. In phase 3 NAVIGATOR study (NCT03347279), tezepelumab significantly reduced annualized exacerbation rate (AAER) versus placebo in severe, uncontrolled This exploratory analysis evaluated efficacy of participants evidence allergic Methods Patients (12–80 years old) receiving medium‐ or high‐dose inhaled corticosteroids and ≥ 1 additional controller medication, without oral corticosteroids, were...
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTDipolar Correlation NMR Spectroscopy of a Membrane ProteinJanet M. Griffiths, K. V. Lakshmi, Andrew E. Bennett, Jan Raap, C. van der Wielen, Johan Lugtenburg, Judith Herzfeld, and Robert G. GriffinCite this: J. Am. Chem. Soc. 1994, 116, 22, 10178–10181Publication Date (Print):November 1, 1994Publication History Published online1 May 2002Published inissue 1 November...
The Information Age is upon us. very structure of society shifting, challenging librarians and other information professionals. They will have to accomodate growing needs more demanding requirements, keep up with master revolutionary technologies, continue provide accurate, precise timely economically. How they meet future challenges depends a large degree on the competencies acquire through education, training, experience. This book presents results project funded by Department Education,...